On May 18, his office announced that an 82-year-old man has been diagnosed with Grade Group 5 prostate cancer—characterized by a Gleason score of 9—and evidence of bone metastases. A recent workup prompted by worsening urinary symptoms revealed the aggressive disease, though doctors note it remains hormone-sensitive, offering a range of possible treatments.
Despite the concerning spread to his skeleton, there are no signs that the cancer has yet reached distant organs or nearby lymph nodes. His care team is now exploring options—from hormone therapy to targeted radiation—in consultation with the patient and his family.
Just last year, routine exams had shown no serious issues, and a small lesion detected during a 2023 biopsy turned out to be basal cell carcinoma, which was fully removed. Now, with this new diagnosis, the focus is on balancing effective intervention with quality of life, guided by the patient’s preferences and overall health.